Completed a proof-of-concept clinical study for its lead Rheumatoid Arthritis (RA) product candidate in December 2024, showing promising results. Launched RaphaWell, a proprietary natural formula for RA support, as a clinically tested dietary supplement in the U.S. in August 2025. Filed a provisional patent application in November 2025 for its cannabinoid-based technology platform for neutrophil-dominant autoimmune diseases, including RA, psoriatic arthritis, inflammatory bowel disease, systemic lupus erythematosus, and gout. Reported a net loss of $1.279 million for the year ended December 31, 2025, a decrease from $1.519 million in 2024. Accumulated deficit reached $10.168 million as of December 31, 2025. Cash and cash equivalents were approximately $0.05 million ($45 thousand) as of December 31, 2025. Management believes existing cash will only fund operations through the third quarter of 2026, raising substantial doubt about its ability to continue as a going concern. Developing novel asthma product candidates in the pre-clinical stage, leveraging COVID-19 research. Relies heavily on third parties for manufacturing, clinical trials, and API supply. Extended service agreements for CEO, CFO, and CTO until December 2026 or 2027, with adjusted compensation for CTO and CFO.